Curated News
By: NewsRamp Editorial Staff
April 24, 2025
Tonix Pharmaceuticals Highlights Positive Data on TNX-801 Vaccine at World Vaccine Congress
TLDR
- Tonix Pharmaceuticals presented positive preclinical data on its single-dose mpox vaccine candidate, TNX-801, potentially offering broad application during global health emergencies.
- TNX-801, a minimally replicative live-virus vaccine, demonstrated efficacy in protecting animals against both mpox and rabbitpox, with lasting six-month protection.
- TNX-801 aligns with the WHO's target profile, providing hope for improved public health in managing current and future mpox outbreaks on a global scale.
- Tonix Pharmaceuticals' presentation at World Vaccine Congress 2025 showcased TNX-801's successful protection against multiple diseases, promising advancements in vaccine development.
Impact - Why it Matters
This news matters as Tonix Pharmaceuticals' TNX-801 vaccine candidate shows promising results in protecting against mpox and rabbitpox, aligning with global health emergency standards. The development of such vaccines is crucial for public health preparedness and response to infectious disease outbreaks.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) presented positive preclinical data on its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025. The oral presentation highlighted TNX-801's efficacy in protecting animals against both mpox and rabbitpox, with durable protection lasting six months. The vaccine aligns with the World Health Organization's preferred target profile, offering potential for broad application in current and future mpox outbreaks.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Highlights Positive Data on TNX-801 Vaccine at World Vaccine Congress
